Avelumab for Urothelial Carcinoma: An Interview With Thomas Powles, MBBS, MRCP, MD

The FDA recently approved avelumab (Bavencio®, EMD Serono, Inc.) for patients with advanced urothelial carcinoma (UC). Thomas Powles, MBBS, MRCP, MD, discusses with i3 Health the implication of this approval and future steps for research and offers community oncologists advice on treating this patient population. What are the most challenging aspects of treating patients with locally advanced or metastatic UC? Thomas Powles, MBBS, MRCP, MD: The overall survival outcomes are poor for the disease....
Continue reading

FDA Approves Avelumab for Advanced Urothelial Carcinoma

First-line cisplatin-based chemotherapy prolongs survival in patients with advanced urothelial carcinoma (UC), but disease progression usually occurs within 8 months, and currently no standard second-line therapies are available. Avelumab (Bavencio®, EMD Serono, Inc.), a fully human anti-PD-L1 IgG1 antibody, has shown to have an acceptable safety profile and success in treating this patient population. Based on this evidence, the FDA has now approved avelumab to treat patients with locally advan...
Continue reading

Avelumab/Axitinib Approved: Advanced Renal Cell Carcinoma

​The FDA has approved avelumab (Bavencio®, EMD Serono, Inc.) in combination with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for advanced renal cell carcinoma (RCC). Avelumab is an anti–programmed death ligand 1 (anti–PD-L1) antibody, a type of immune checkpoint inhibitor. Axitinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), improves tumor infiltration by immune cells. It has antiangiogenic activity, meaning that it prevents tumors from gro...
Continue reading

Advanced Renal-Cell Carcinoma: Potential First-Line Treatment

​A phase 3 clinical trial has found that in previously untreated patients with advanced renal-cell carcinoma (RCC), avelumab plus axitinib improves progression-free survival and objective response compared with sunitinib. Sunitinib is an antiangiogenic drug, meaning that it prevents tumors from growing their own blood vessels. It is considered standard of care as a first-line therapy for patients with advanced RCC. However, many patients either have inherent resistance to antiangiogenic drugs or...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.